[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554840":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":47,"collaborators":25,"id":49,"slug":25,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":25,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":25,"overallStatus":71,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"oXiris","EXPERIMENTAL","The subjects will be accepted oXiris filter at the first treatment session for 72 hours.",[13],"Device: CRRT filter",{"label":15,"type":16,"description":17,"interventionNames":18},"ST 150","ACTIVE_COMPARATOR","The subjects will be accepted ST 150 filter at the first treatment session for 72 hours.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","CRRT filter","The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml\u002Fmin; replacement fluid flow 30-35ml\u002Fkg\u002Fh (100% post-dilution).",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"mingli zhu, MD","CONTACT","86-13701903155","millionzhu525@126.com",[33],{"facility":34,"status":25,"city":35,"state":25,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","Shanghai","200127","China",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":46,"role":29,"phone":30,"phoneExt":25,"email":25},"Mingli Zhu",{"type":48,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100554840",false,"NCT06504316","OXiris for Abdominal SEptic Shock (OASES Study)","A Multicenter, Randomized Control Clinical Trial on the Effect of Adsorptive Filter oXiris on Hemodynamics of Abdominal Septic Shock Patients","OASES","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Weight ≥30 kg;\n3. Intra-abdominal infection (blood or abdominal drainage fluid culture positive for Gram-negative bacteria or suspected to be caused by a Gram-negative agent);\n4. Diagnostic septic shock (Sepsis 3.0): Sepsis was defined as \"life-threatening organ dysfunction caused by a dysregulated host response to infection\" with organ dysfunction defined as an increase in qSOFA ⩾2 points. Septic shock was defined as sepsis requiring vasoactive therapy to maintain mean arterial pressure (MAP) ⩾ 65 mmHg and lactate elevation to \\>2 mmol\u002FL despite adequate volume resuscitation;\n5. The dose of norepinephrine⩾0.4ug\u002Fkg\u002Fmin;\n6. PCT⩾50ug\u002FL, and\u002For IL-6⩾1000pg\u002Fml;\n7. AKI stage II\u002FIII (Kidney Disease Improving Global Outcomes, KDIGO grade);\n8. Duration of septic shock ≤48 hours.\n\nExclusion Criteria:\n\n1. Patients with highly contagious infectious diseases, such as tuberculosis;\n2. Pregnant and lying-in woman or lactation period;\n3. Infection of other sites (no abdominal infection like pneumonia, central nervous system infection and so on);\n4. CRRT cannot be performed for various reasons;\n5. Death is expected within 48 hours of admission to the ICU;\n6. Previous renal replacement therapy;\n7. Patients that underwent cardio-pulmonary resuscitation (CPR);\n8. Patients who will not sign the informed consent form.","ALL","18 Years",{"count":59,"type":60},192,"ESTIMATED","INTERVENTIONAL",[63],"NA","This study innovatively utilizes multi-modal hemodynamic monitoring (Norepinephrine equivalence, NEE+Pulse indicator Continuous Cariac output, PiCCO) to investigate the optimal timing of initiation of oXiris in abdominal infection-associated septic shock patients and to investigate prognosis on sepsis phenotypes undergoing oXiris therapy.",[66,67,68,69,70],"Septic Shock","Abdominal Sepsis","Multi Organ Failure","Blood Purification","AKI - Acute Kidney Injury","NOT_YET_RECRUITING","2024-07-10",{"date":74,"type":75},"2024-07-16","ACTUAL",{"date":77,"type":60},"2024-08-15",{"date":79,"type":60},"2027-05-31",{"name":5,"class":6},1]